What question did this study set out to answer?

To assess the impact of myeloma and other hematologic malignancies on mortality and clinical outcomes in ADHF patients.

December 8, 2025BloodOpen Access

Exploring the interplay of myeloma and acute decompensated heart failure: Mortality and comorbidity insights

View Full Paper

Ask AI

Bookmark

Authors

NRNicholas RomaSt. Luke's University Health Network

Discussion

Member takes

Implication

Analysis reveals myeloma significantly increases mortality and comorbidity in acute decompensated heart failure cases, suggesting complex disease interactions.

Key Points

To assess the impact of myeloma and other hematologic malignancies on mortality and clinical outcomes in ADHF patients.
Used National Inpatient Sample data from 2018 to 2022
Identified over 6 million ADHF hospitalizations and stratified by myeloma and related malignancies
Employed logistic regression models to estimate odds ratios for in-hospital mortality and other outcomes.
ADHF patients with myeloma had a mortality rate of 4.37% compared to 2.73% without malignancies
Adjusted odds ratio for mortality in myeloma group was 1.26
Higher rates of chronic kidney disease and transfusion needs were observed in myeloma patients.

Cite This Study

Nicholas Roma (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236de8d https://doi.org/10.1182/blood-2025-2199

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals myeloma significantly increases mortality and comorbidity in acute decompensated heart failure cases, suggesting complex disease interactions.

Exploring the interplay of myeloma and acute decompensated heart failure: Mortality and comorbidity insights

Discussion

Member takes

Implication

Key Points

Cite This Study

Exploring the interplay of myeloma and acute decompensated heart failure: Mortality and comorbidity insights

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider